The public hearing on the US Center for Drug Evaluation and Research’s proposal to withdraw accelerated approval of Covis Pharma’s preterm birth prevention drug Makena (hydroxyprogesterone caproate) appears on track for 2022.
Although a hearing date is not yet announced, presiding officer Celia Witten is asking CDER and Covis to provide specific...








